In the present study, ACVR2A-KO HCC tissues were enriched with Treg cells and insusceptible to anti-PD-1 therapy (Figures S15B–S15E), and the combination with the MCT4 inhibitor VB124 could ameliorate the CD8/Foxp-3 ratio and attenuate tumor growth (Figures 7E–7L). Here, ACVR2A is linked to neoplasm.